



AGENDA FOR THE ACCELERATE ANNUAL CONFERENCE

Shifting Gears in Paediatric Cancer Innovation

'The Dual engine approach': To cure more children and adolescents with cancer, we must both accelerate the smart development and use of adult cancer innovations and build new paediatric-first development pathways to incentivize the development of specific paediatric oncology drugs.

DAY 1 – 5th FEB

09:00 – 10:00	Welcome Coffee
	Introduction
10:00 - 10:20	<ul style="list-style-type: none">• Vision and Mission of ACCELERATE - <i>Nicole Scobie, ACCELERATE</i>• Goals of the Conference - The Thread - <i>"Dual engine approach"</i> - <i>Gilles Vassal, ACCELERATE</i>
	ACKNOWLEDGING TODAY'S REALITY Understanding the global framework for paediatric oncology drug development for the next 5 years
10:20 - 11:00	<ul style="list-style-type: none">• Global Oncology trends - <i>Murray Aitken, Iqvia Institute (UK)</i>• Global economic impact on biopharmaceuticals.• Discussion: Potential effects on pediatric cancer research and drug development
	Session I - Improving generation of evidence in paediatric oncology drug development
11:10- 12:30	<ul style="list-style-type: none">• Use of Real Word Data: SACHA International - <i>Pablo Berlanga, Gustave Roussy (France)</i>• Advancing Childhood Cancer Academic-Industry Collaborative Platform - <i>Pamela Kearns, University of Birmingham (UK)</i>• ACCELERATE Working group on Patient Reported Outcomes – <i>Franziska Helmberg, Medical University Innsbruck (Germany)</i>• Panel Discussion

12:30 - 1:30

Lunch

Advocates networking (closed session)

1:30 - 3:30

CALLING FOR A SHIFT

Session II - Accelerating the development of specific paediatric oncology products

- Learning from the development of antiGD2 antibodies for the treatment of neuroblastoma: an academic perspective - *Steven DuBois, Dana-Farber Cancer Institute (USA)*
- Development of Cuprion™ for the treatment of Wilson disease - *Naseem Amin/Omar Camille Kamlin, Orphalan (France)*
- Generating scientific evidence for specific paediatric drug development - The ITCC-LifeArc project - *Jan Molenaar, Princess Maxima Center for Paediatric Oncology (The Netherlands)*
- New European initiatives (Biotech Act, European Innovation Act)
- Panel discussion

3:30 - 4:00

Coffee break + group photo

4:00 - 4:45

Paediatric Strategy and Impact Forums

- Results of the Paediatric Strategy Forum on Antibody Drug - *Margaret Macy, Children's Hospital Colorado (USA)*
- Presentation of the 2026 Paediatric Strategy Forum
- Plan for future Forums and workshop – *Elizabeth Fox, St Jude Children's Research Hospital (USA)*

4:45 - 6:30

Break-out sessions (on site and by zoom)

- **Topic 1:** Accelerating paediatric development of adult innovations: how do we get early conduct of studies leading to regulatory approvals?
- **Topic 2:** Developing specific paediatric oncology drugs: what are the gaps in knowledge, barriers and constraints? What are the drivers to get paediatric oncology in Start-up and Biotech companies?

6:30

End of day 1



www.accelerate-platform.org

WE GRATEFULLY ACKNOWLEDGE THE GENEROUS SUPPORT OF OUR ACCELERATE PARTNERS:



CHALLENGING THE SYSTEM**Session III - Will the regulatory framework support and incentivize?**

8:30 - 10:30

- Update on regulatory changes for paediatric development of adult anticancer drugs in Europe - *Dominik Karres, European Medicines Agency (The Netherlands)*
- Update on regulatory changes for paediatric development of adult anticancer drugs in North America - *Martha Donoghue, Food and Drug Administration, (USA)*
- Changes in the Declaration of Helsinki for vulnerable populations: a paradigm change - *Rieke van der Graaf, MedEthicsEU (The Netherlands)*
- Panel discussion: What role for ACCELERATE in the changing regulatory environment?

10:30 - 11:00

Coffee break

11:00 - 1:00

DRIVING TO ACTION**Session IV - Accelerating drug paediatric development of adult innovations**

- Access to drug for investigator supported trials - *Brenda Weigel, St Jude Children's Research Hospital (USA)*
- Cross border access to therapeutic innovations in Europe - *Francisco Bautista Sirvent, Princess Maxima Centrum (The Netherlands)*
- Facilitating access to clinical trials in Canada - *Daniel Morgenstern, Hospital for Sick Children (Canada)*
- **Report from Break Out Session topic 1 and proposing a plan**
Accelerating paediatric development of adult innovations: how do we get early conduct of studies leading to regulatory approvals?

1:00 - 2:00

Lunch

- **Charity Partners of ACCELERATE networking (closed session)**

2:00 - 3:30

Session V - Developing pediatric-specific oncology drugs

- 2 presentations from start-ups /biotech developing a paediatric oncology innovation
- **Report from Break Out Session topic 2**
Developing specific paediatric oncology drugs: what are the gaps in knowledge, barriers and constraints? What are the drivers to get paediatric oncology in Start-up and Biotech companies?

3:30 - 4:15

Session VI - Building the ACCELERATE work plan**Chairs: Nicole Scobie and Gilles Vassal, ACCELERATE**

4:15 - 4:30

Wrap up

4:30

End of day 2